TY  - JOUR
AU  - Forster, Martin
AU  - Hackshaw, Allan
AU  - De-Pas, Tommaso
AU  - Cobo, Manuel
AU  - Garrido, Pilar
AU  - Summers, Yvonne
AU  - Dingemans, Anne-Marie C
AU  - Flynn, Michael
AU  - Schnell, David
AU  - von-Wangenheim, Ute
AU  - Loembe, Arsene-Bienvenu
AU  - Kaiser, Rolf
AU  - Lee, Siow Ming
PY  - 2018
DO  - 10.1016/j.lungcan.2018.03.007
UR  - http://hdl.handle.net/10668/12447
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment...
LA  - en
PB  - Elsevier
KW  - Nintedanib
KW  - Non-small cell lung cancer
KW  - Squamous
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cisplatin
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Treatment Outcome
KW  - Gemcitabine
TI  - A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
TY  - research article
VL  - 120
ER  -